Annual ROE
-150.37%
-46.15%-44.28%
31 December 2023
Summary:
Monopar Therapeutics annual return on equity is currently -150.37%, with the most recent change of -46.15% (-44.28%) on 31 December 2023. During the last 3 years, it has fallen by -110.19% (-274.24%). MNPR annual ROE is now -349.40% below its all-time high of -33.46%, reached on 31 December 2019.MNPR ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-107.45%
+3.14%+2.84%
30 September 2024
Summary:
Monopar Therapeutics quarterly return on equity is currently -107.45%, with the most recent change of +3.14% (+2.84%) on 30 September 2024. Over the past year, it has increased by +5.86% (+5.17%). MNPR quarterly ROE is now -200.90% below its all-time high of -35.71%, reached on 30 September 2018.MNPR Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MNPR ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -44.3% | +5.2% |
| 3 y3 years | -274.2% | -168.4% |
| 5 y5 years | -222.3% | -54.3% |
MNPR ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -274.2% | at low | -168.4% | +7.3% |
| 5 y | 5 years | -349.4% | at low | -183.7% | +7.3% |
| alltime | all time | -349.4% | +12.6% | -200.9% | +44.9% |
Monopar Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -107.45%(-2.8%) |
| June 2024 | - | -110.59%(-0.0%) |
| Mar 2024 | - | -110.62%(-4.6%) |
| Dec 2023 | -150.37%(+44.3%) | -115.97%(+2.3%) |
| Sept 2023 | - | -113.31%(+12.3%) |
| June 2023 | - | -100.87%(+10.7%) |
| Mar 2023 | - | -91.13%(+17.2%) |
| Dec 2022 | -104.22%(+116.9%) | -77.77%(+18.8%) |
| Sept 2022 | - | -65.46%(+13.3%) |
| June 2022 | - | -57.79%(+20.2%) |
| Mar 2022 | - | -48.06%(+17.0%) |
| Dec 2021 | -48.06% | -41.06%(+2.5%) |
| Sept 2021 | - | -40.04%(+5.7%) |
| June 2021 | - | -37.88%(-6.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | -40.31%(-7.7%) |
| Dec 2020 | -40.18%(+20.1%) | -43.68%(+10.9%) |
| Sept 2020 | - | -39.39%(-8.1%) |
| June 2020 | - | -42.87%(-5.4%) |
| Mar 2020 | - | -45.32%(-24.5%) |
| Dec 2019 | -33.46%(-28.3%) | -60.03%(-13.8%) |
| Sept 2019 | - | -69.66%(+16.0%) |
| June 2019 | - | -60.05%(+14.3%) |
| Mar 2019 | - | -52.52%(+28.0%) |
| Dec 2018 | -46.66%(-72.9%) | -41.02%(+14.9%) |
| Sept 2018 | - | -35.71%(-81.7%) |
| June 2018 | - | -194.97%(+5.6%) |
| Mar 2018 | - | -184.64%(+7.3%) |
| Dec 2017 | -172.10%(+310.9%) | -172.10% |
| Dec 2016 | -41.88% | - |
FAQ
- What is Monopar Therapeutics annual return on equity?
- What is the all time high annual ROE for Monopar Therapeutics?
- What is Monopar Therapeutics annual ROE year-on-year change?
- What is Monopar Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Monopar Therapeutics?
- What is Monopar Therapeutics quarterly ROE year-on-year change?
What is Monopar Therapeutics annual return on equity?
The current annual ROE of MNPR is -150.37%
What is the all time high annual ROE for Monopar Therapeutics?
Monopar Therapeutics all-time high annual return on equity is -33.46%
What is Monopar Therapeutics annual ROE year-on-year change?
Over the past year, MNPR annual return on equity has changed by -46.15% (-44.28%)
What is Monopar Therapeutics quarterly return on equity?
The current quarterly ROE of MNPR is -107.45%
What is the all time high quarterly ROE for Monopar Therapeutics?
Monopar Therapeutics all-time high quarterly return on equity is -35.71%
What is Monopar Therapeutics quarterly ROE year-on-year change?
Over the past year, MNPR quarterly return on equity has changed by +5.86% (+5.17%)